Achaogen is a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multidrug resistant (MDR) gram-negative infections

The Challenge: According to the Centers for Disease Control and Prevention (CDC), at least 2 million people become infected with bacteria that are resistant to antibiotics each year in the United States. The CDC has also characterized carbapenem-resistant Enterobacteriaceae (CRE) as “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action”. New antibacterials for gram-negative bacterial infections are desperately needed. (Source: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Antibiotic Resistance Threats in the United States, 2013.)

Our Approach: We are committed to identifying and developing product candidates to treat multi-drug resistant (MDR) gram-negative infections. We have in-depth knowledge about the relationship between compound structure and potency against gram-negative bacteria through our work on multiple antibiotic classes. This expertise has allowed us to identify and build a portfolio of product candidates for the treatment of infections due to MDR gram-negative pathogens. We developed plazomicin which was FDA-approved in the United States in 2018. We are developing a second product candidate, C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination with the potential to treat patients with complicated urinary tract infections due to MDR pathogens. We are also developing a new aminoglycoside program, which is supported by funding from CARB-X. 

Our People: We have deep expertise in the discovery, development and commercialization of new antibacterial drugs, including a fundamental expertise in the relationship between chemical structure and gram-negative potency. In addition, our interdisciplinary teams made up of seasoned professionals enable us to design and conduct large, global clinical trials.